article thumbnail

DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes

Physician's Weekly

WEDNESDAY, June 18, 2025 (HealthDay News) — The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in people with diabetes, according to a study published online June 9 in JAMA Internal Medicine. Pilla, M.D., Pilla, M.D.,

article thumbnail

Postural Sway Velocity Effective for Assessing Diabetic Peripheral Neuropathy

Physician's Weekly

Postural sway velocity as a screening tool in diabetic peripheral neuropathy represents a potential early marker of balance impairment and fall risk. The 2025 annual meeting of the Peripheral Nerve Society (PNS) took place in Edinburgh, Scotland, from May 17, 2025 to May 20, 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes

Physician's Weekly

from the Velocity Clinical Research Center at Medical City Dallas, and colleagues conducted a phase 3 trial involving participants with type 2 diabetes treated only with diet and exercise, an HbA1c level of ≥7.0 Abstract/Full Text (subscription or payment may be required) More Information Copyright © 2025 HealthDay.

52
article thumbnail

Maria Ansari, MD, FACC, named to Modern Healthcare’s list of 50 Most Influential Clinical Executives

Permanente Medicine

June 10, 2025) — Maria Ansari, MD, FACC , co-CEO of The Permanente Federation at Kaiser Permanente, has been named to Modern Healthcare’s list of 50 Most Influential Clinical Executives for 2025. The result is high-quality, high-value care within an integrated system — improving lives and shaping the future of health care.”

Clinic 59
article thumbnail

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

Physician's Weekly

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics , a gene-editing startup, for about $1 billion upfront. The treatment is being tested in a Phase 1b clinical trial and has received fast-track designation from the U.S. The deal, announced June 17, includes a cash offer of $10.50

article thumbnail

What to Expect at the ADA 85th Scientific Sessions: Obesity, Nutrition, Prevention, and More

Physician's Weekly

The ADA’s 85th Scientific Sessions will highlight breakthroughs in obesity and diabetes care, including GLP-1 therapies, tech advances, and prevention tools. Per a press release by the ADA, attendees can expect to see clinical research showcasing the latest innovations in obesity care. Roughly 42% (109.9

article thumbnail

Redesigning Primary Care Workflows to Optimize Obesity Management

Physician's Weekly

As rates of obesity continue to rise alongside new therapeutic options, a team of researchers at the 85th Scientific Sessions of the American Diabetes Association (ADA) will present findings from PATHWEIGH , a pragmatic clinical trial designed to embed evidence-based obesity care directly into primary care workflows.